Newamsterdam Pharma’s CAO’s Latest Stock Flip: Buying Big at Low Prices Amid Frequent Option Sales Raises Investor Speculation on Future Pipeline Success

Insider Activity at Newamsterdam Pharma: What the Numbers Say

On January 27 2026, Chief Accounting Officer Louise Kooij bought 39,816 shares of NAMS at $10.90, boosting her stake to 64,169 shares. The purchase occurred just weeks after a string of sales—both ordinary shares and options—that saw her holdings dip to 24,353 shares in late January. The timing of this buy is noteworthy: the stock is trading near $31.88, a level roughly 24 % below its 52‑week high and just above its low, while the company’s earnings remain negative (P/E = –17.21). In a volatile market, a CAO’s purchase can be interpreted as a signal of confidence, yet the context of repeated sales warrants a careful read.

Implications for Investors

Kooij’s recent transactions suggest a pattern of active portfolio management. Over the past month she has alternated between buying and selling, with option sales outnumbering share purchases. This behavior may reflect a strategic approach to balance liquidity and exposure as the company progresses through its late‑stage clinical pipeline. For investors, the CAO’s buy at a low price point could be viewed as a positive, implying belief in a rebound as the company moves toward commercialization. However, the persistent sell activity—especially the large option sales that increase her option balance—could indicate a hedging strategy rather than outright bullishness. Market watchers should therefore monitor whether the CAO’s share purchases are isolated or part of a broader insider trend.

What This Means for Newamsterdam’s Future

Newamsterdam’s stock has been under pressure, falling from a November high of $42 to below $32 today, while its valuation remains modest. The insider activity may hint at the company’s internal expectations: if the CAO feels that the pipeline milestones are on track, a purchase could precede a positive earnings outlook. Conversely, option sales could be a pre‑emptive measure against potential downside risk, perhaps tied to upcoming regulatory filings or partnership announcements. The recent buyer/seller swings could therefore be a signal of cautious optimism, with insiders hedging while positioning for a possible upside.

Louise Kooij: A Profile of Insider Behavior

Kooij’s transaction history paints a picture of a disciplined, risk‑aware officer. She has consistently used option sales to build a large option balance (now 105,746 shares) while maintaining a substantial share position. Her average purchase price hovers around $10–12, significantly below the current market price, indicating a long‑term view. The pattern of buying low and selling high, coupled with option strategies, suggests she is comfortable with volatility and seeks to protect her holdings as the company navigates regulatory and market challenges. For investors, Kooij’s moves can be interpreted as a balance between confidence in Newamsterdam’s therapeutic pipeline and prudence in managing exposure.

Bottom Line for Investors

In a market where NAMS is trading below its peak and the company’s earnings are negative, a CAO’s purchase can be a bullish signal—but one that must be weighed against frequent option sales. Investors should watch for future insider activity, especially around key clinical milestones, and consider whether the CAO’s strategy aligns with your risk tolerance and investment horizon.